Home / Press / Apotal Group sells online pharmacy’s mail-order...

Apotal Group sells online pharmacy’s mail-order business and diabetes arm to Zur Rose Group

26/06/2020

Stuttgart – Company founder Heinz-Peter Fichter and other shareholders have sold the mail-order business of online pharmacy Apotal and its diabetes division to the listed Zur Rose Group of Switzerland. Specifically, the deal covers mail-order sale of over-the-counter and prescription drugs, health and beauty products and diabetes-related mail-order operations. The parties agreed not to disclose the purchase price. The transaction is currently awaiting approval from Germany’s Federal Cartel Office and is expected to close in the third quarter of 2020.

A CMS team headed by lead partner Dr Christoph Lächler advised the founder of the Apotal Group, Heinz-Peter Fichter, and other shareholders on all legal aspects of the sales process. The particular challenge was structuring the transaction in compliance with pharmacy law.

Apotal, which is based in Bad Rothenfelde, was established in 1980 by Heinz-Peter Fichter and is now one of the best known and largest pharmacy brands in Germany. The firm has also built up a market-leading network focusing on diabetes patients, offering a wide range of products and services related to this chronic disease. In recent years, Apotal has grown annually in the high single-digit percentage range, while also achieving positive EBITDA. With the 1.1 million additional Apotal customers, the Zur Rose Group is increasing its lead over its nearest rival in Europe by 50%.

The Switzerland-based Zur Rose Group is Europe’s largest e-commerce pharmacy and a leading medical wholesaler in Switzerland. It also operates the leading marketplace in southern Europe for health and hygiene products customarily sold in a pharmacy. The company has an international presence with strong brands, including Germany’s best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people across its locations in Switzerland, Germany, the Netherlands, Spain and France. In 2019, it generated sales of CHF 1,569 million (including medpex) from serving around seven million active customers in core European markets. Zur Rose Group AG’s shares are listed on the SIX Swiss Exchange.

CMS Germany

Dr Christoph Lächler, Lead Partner
Dr Jochen Lux, Partner
Daniel Mahn, Senior Associate
Benedikt Pittrof, Associate
Laura Rejano, Associate, all Corporate/M&A
Dr Boris Alles, Counsel, Labor, Employment & Pensions
Prof. Heralt Hug, Partner
Stefan Schreiber, Senior Associate, both Intellectual Property
Dr Jörn Witt, Partner
Dr Susanne Pech, Counsel
Dr Friederike von Zezschwitz, Associate, all Regulatory
Dr Dirk Schauer, Counsel, Private Clients
Aylin Kocak, Senior Associate, Real Estate & Public
Dr Martin Mohr, Counsel, Tax Law
Dr Rolf Hempel, Partner, Competition & EU

CMS Switzerland

Dr Daniel Jenny, Partner

Press Contact
[email protected]

Related people

Christoph Lächler
Dr. Christoph Lächler
Partner
Stuttgart
Jochen Lux
Dr. Jochen Lux
Partner
Leipzig
Daniel Mahn
Daniel Mahn
Senior Associate
Stuttgart
Benedikt Pittrof
Benedikt Pittrof
Associate
Leipzig
Laura Rejano
Associate
Stuttgart
Boris Alles
Dr. Boris Alles
Counsel
Frankfurt
Heralt Hug
Prof. Dr. Heralt Hug
Partner
Leipzig
Stefan Schreiber
Stefan Schreiber
Senior Associate
Leipzig
Dr. Jörn Witt, LL.M. (University of London)
Partner
Hamburg
Susanne Pech
Dr. Susanne Pech
Counsel
Hamburg
Friederike Zezschwitz
Dr. Friederike von Zezschwitz
Associate
Hamburg
Dirk Schauer
Dr. Dirk Schauer
Counsel
Stuttgart
Aylin Kocak
Aylin Kocak
Senior Associate
Stuttgart
Martin Mohr
Dr. Martin Mohr
Counsel
Stuttgart
Rolf Hempel
Dr. Rolf Hempel
Partner
Stuttgart
Jenny Daniel
Dr Daniel Jenny, LL.M.
Partner
Zurich
Show more Show less